749927-69-3Relevant articles and documents
The invention relates to a synthetic method of. Intermediate and synthetic method
-
Paragraph 0079-0084, (2021/11/27)
The invention belongs to the technical field of drug synthesis, and discloses a synthesis method, an intermediate and a synthesis method of amideamine, and solves the problems of complex operation, high production cost, no suitability for industrialization and environmental friendliness in the prior art. To the formula VIII, a compound of formula VII is produced by a one-pot method, a compound of formula VII is subjected to a one-pot method to form an intermediate formula IV compound of, and a compound of formula IV and a compound of formula II are cyclized to obtain the compound of formula I. The method is simple to operate, few in procedures, low in production cost, and high in product yield and purity.
Method for synthesizing enzalutamide intermediate
-
, (2019/04/04)
The invention discloses a method for synthesizing an enzalutamide intermediate. The method is characterized by comprising the following steps: adding 4-bromo-2-fluorobenzoic acid and sulfoxide chloride into an organic solvent, evacuating and introducing nitrogen, and carrying out a reaction at a temperature of 80-100 DEG C; evaporating the solvent to dryness so as to obtain 4-bromo-2-fluorobenzoylchloride after the reaction ends, adding the organic solvent into the 4-bromo-2-fluorobenzoyl chloride, slowly adding an aqueous solution of methylamine to regulate the pH value of the reaction solution to be 8-9, and continuing to carry out the reaction; extracting with the organic solvent after the reaction ends, collecting the organic phase, and evaporating the solvent to dryness, thereby obtaining the 4-bromo-2-fluoro-N-methylbenzamide. According to the method disclosed by the invention, the 4-bromo-2-fluorobenzoic acid and 2-aminoisobutyric acid are taken as the raw materials, the product is prepared by a substitution reaction under the actions of cuprous halide catalysis, ligand assistance and in the presence of an acid-binding agent, and the yield is 75%. However, by virtue of theoptimized conditions, cheap acetylacetone is screened as a ligand, and the cost is greatly reduced.
A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF5) and pentafluoroethyl (C2F5) substituents: Improved antiproliferative agents against prostate cancer
Pertusati, Fabrizio,Ferla, Salvatore,Bassetto, Marcella,Brancale, Andrea,Khandil,Westwell, Andrew D.,McGuigan, Christopher
, p. 1 - 14 (2019/07/10)
SAR studies on bicalutamide, enobosarm and enzalutamide analogues, functionalised with polyfluorinated groups, is presented. Among the novel bicalutamide and enobosarm derivatives synthesised, several displayed significantly improved in vitro anticancer activity, with IC50 values in the low micromolar range against four different prostate cancer cell lines (LNCaP, VCaP, DU-145 and 22Rv1), showing up to 48-fold increase in comparison with the parent structures. In particular, SF5 enobosarm analogues were found to be most potent compounds, full AR antagonists and with favourable ADME properties. The most promising compound (48a) was evaluated for its in vivo efficacy in PC xenograft mouse model (22Rv1) with results comparable to the standard-of-care docetaxel.
